Patrick S Ward

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/687904/publications.pdf

Version: 2024-02-01

19	16,211	430754	794469
papers	citations	18	19
		h-index	g-index

19	19	19	19469
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. Journal of Biological Chemistry, 2018, 293, 20051-20061.	1.6	11
2	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer Discovery, 2017, 7, 494-505.	7.7	94
3	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports, 2014, 9, 1841-1855.	2.9	237
4	The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization. Journal of Biological Chemistry, 2013, 288, 3804-3815.	1.6	141
5	SnapShot: Cancer Metabolism Pathways. Cell Metabolism, 2013, 17, 466-466.e2.	7.2	43
6	Induction of sarcomas by mutant IDH2. Genes and Development, 2013, 27, 1986-1998.	2.7	135
7	Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes and Development, 2013, 27, 1974-1985.	2.7	165
8	Identification of additional IDH mutations associated with oncometabolite R(â^')-2-hydroxyglutarate production. Oncogene, 2012, 31, 2491-2498.	2.6	172
9	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483, 479-483.	13.7	1,668
10	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	13.7	1,693
11	Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6904-6909.	3.3	323
12	Signaling in Control of Cell Growth and Metabolism. Cold Spring Harbor Perspectives in Biology, 2012, 4, a006783-a006783.	2.3	237
13	Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell, 2012, 21, 297-308.	7.7	2,617
14	Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of Î±-ketoglutarate to citrate to support cell growth and viability. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19611-19616.	3.3	851
15	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting Î±-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, 2010, 17, 225-234.	7.7	1,754
16	Leukemic IDH1 and IDH2 Mutations Result inÂa Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 2010, 18, 553-567.	7.7	2,328
17	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2010, 465, 966-966.	13.7	360
18	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009, 462, 739-744.	13.7	3,315

#	Article	IF	Citations
19	Cyclic AMP triggers glucagon-like peptide-1 secretion from the GLUTag enteroendocrine cell line. Diabetologia, 2007, 50, 2181-2189.	2.9	67